Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Curis (CRIS) reported a quarterly loss of $1.70 per share, better than the Zacks Consensus Estimate of a loss of$1.88, and an improvement from a loss of $2.13 per share a year ago, resulting in an earnings surprise of 9.57$2.93 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 3.20%, and showing an increase from $2.83 million in the same quarter last year [2] - Curis shares have declined approximately 69.2$1.28 on revenues of $2.69 million, and for the current fiscal year, it is -$6.79 on revenues of $8.44 million [7] - The estimate revisions trend for Curis is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Curis belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]